Abstract
The β‐adrenoceptor (AR) is currently classified into β1, β2, and β3subtypes. A third subtype, β3‐AR, was first identified in adipose tissue, but has also been identified in smooth muscle tissue, particularly in the gastrointestinal tract and urinary bladder smooth muscle. There is a predominant expression of β3‐AR messenger RNA (mRNA) in human bladder, with 97% of total β‐AR mRNA being represented by the β3‐AR subtype and only 1.5 and 1.4% by the β1‐AR and β2‐AR subtypes, respectively. Moreover, the presence of β1‐, β2‐, and β3‐AR mRNAs in the urothelium of human bladder has been identified. The distribution of β‐AR subtypes mediating detrusor muscle relaxation is species dependent, the predominant subtype being the β3‐AR in humans. Recent studies have suggested that cAMP‐dependent routes are not exclusive mechanisms triggering the β‐AR‐mediated relaxation of smooth muscle. It has been demonstrated in rats detrusor muscle that cAMP plays a greater role in β‐adrenergic relaxation against basal tone than against KCl‐induced tone and that conversely calcium‐activated K+channels (BKca channels) play a greater role under the latter circumstances. In rat models, β3‐AR agonists increase bladder capacity without influencing bladder contraction and have only weak cardiovascular side effects. Although this evidence points toward the clinical utility of β3‐AR agonists as therapy for overactive bladder (OAB), pharmacological differences exist between rat and human β3‐ARs. Development of compounds with high selectivity for the human β3‐AR, identified by screening techniques using cell lines transfected with the human β1‐, β2‐, and β3‐AR genes, may mitigate against such problems. The association between the tryptophan 64 arginine polymorphism in the β3‐AR gene and idiopathic OAB is discussed. Neurourol. Urodynam. 26:752–756, 2007.

This publication has 73 references indexed in Scilit: